A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 948 participants.

Also called NCT07889648

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 948 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07889648
  • EU CT 2026-526948-13-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07889648. Randomized; no masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-04-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Acronym
ENI-SPIRE-2
Condition
Type 2 Diabetes Mellitus
Intervention (Combination product)
Enicepatide
Intervention (Combination product)
Tirzepatide
Lead sponsor
Hoffmann-La Roche (class: industry)
Collaborator
Chugai Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct07889648
Content hash
e468e4578ef5b97e609d3e47cc03b881750b2b312ccab4bba53c33bc34b3c27e